8-K: Decoy Therapeutics Stockholders Approve Reverse Split, Equity Plan

Decoy Therapeutics Inc. stockholders approved a reverse stock split and a new equity incentive plan at a virtual special meeting held on February 24, 2026.

Summary

• Decoy Therapeutics Inc. held a virtual special meeting of stockholders on February 24, 2026, with 2,696,758 shares of common stock present and entitled to vote.
• Stockholders approved the Decoy Therapeutics Inc. 2026 Equity Incentive Plan.
• Stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse split of outstanding common stock at a ratio in the range of 1-for-4 to 1-for-15, to be determined at the discretion of the Board of Directors.
• Stockholders authorized one or more adjournments of the Special Meeting to solicit additional proxies if needed, but this was not necessary as all proposals passed.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive, as key management proposals were approved, providing flexibility for corporate actions, though the underlying need for a reverse split suggests challenges that warrant continued monitoring.

Positives

• Stockholders approved the 2026 Equity Incentive Plan, which provides a mechanism for attracting and retaining talent through equity compensation.
• Stockholders approved the reverse stock split proposal, granting the Board flexibility to potentially increase the share price and maintain Nasdaq listing compliance.

Negatives

• The necessity for a reverse stock split often indicates a low share price, which can be perceived negatively by the market and may reflect underlying operational or financial challenges.

Future Outlook

The Board of Directors has the discretion to determine the specific ratio for the approved reverse stock split within the 1-for-4 to 1-for-15 range. The approved 2026 Equity Incentive Plan will be implemented to facilitate future equity compensation for employees.

Industry Context

StockSavvy.ai notes that reverse stock splits are often utilized by biotechnology companies like Decoy Therapeutics to increase their share price, potentially to meet minimum bid price requirements for continued listing on exchanges such as Nasdaq, which is common in the volatile biotech sector. The approval of an equity incentive plan is standard practice to attract and retain talent in this competitive industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a reduction in the number of shares held, with a proportional increase in share price per share, following the reverse stock split. The total value of their holdings should remain unchanged immediately after the split.
• Employees: The approval of the 2026 Equity Incentive Plan provides a mechanism for future equity-based compensation, potentially impacting employee motivation and retention.

Next Steps

• The Board of Directors will determine the exact ratio for the reverse stock split within the approved range of 1-for-4 to 1-for-15.
• The Decoy Therapeutics Inc. 2026 Equity Incentive Plan will be implemented.

Key Dates

Recommendation

The approval of the reverse stock split provides the company with a tool to address potential listing compliance issues and improve its share price, which could be seen as a positive for market perception. The new equity incentive plan is also beneficial for talent retention. However, the underlying necessity for a reverse split often signals previous stock price weakness, and the actual impact on long-term shareholder value remains to be seen. Investors should hold and monitor the company's operational performance and the execution of the reverse split.

Keywords

Decoy Therapeutics, DCOY, Reverse Stock Split, Equity Incentive Plan, Stockholder Meeting, Corporate Governance, Nasdaq Listing